-

CNC Deadline: Rosen Law Firm Urges Centene Corporation (NYSE: CNC) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025. Centene describes itself as a “leading healthcare enterprise.”

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Centene Corporation (NYSE: CNC) Misled Investors Regarding its Business Operations.

According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene’s expected revenue guidance and adjusted diluted earnings per share (“EPS”) for the 2025 fiscal year. Defendants’ statements included, among other things, confidence in Centene’s enrollment and morbidity rates, as well as strong retention rates in Centene’s Medicare business. Defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene’s enrollment and morbidity rates.

What Now: You may be eligible to participate in the class action against Centene Corporation. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 8, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

The Rosen Law Firm, P.A.

NYSE:CNC

Release Versions

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

More News From The Rosen Law Firm, P.A.

Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) resulting from allegations that ImmunityBio, Inc. may have issued materially misleading business information to the investing public. So What: If you purchased ImmunityBio, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc...

Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 2024 and January 9, 2026. Atara describes itself as a company that “develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 8...

Rosen Law Firm Urges Coty Inc. (NYSE: COTY) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Coty Inc. (NYSE: COTY) between November 5, 2025 and February 4, 2026. Coty describes itself as a company that “together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Ros...
Back to Newsroom